Welcome to our dedicated page for Viking Therapeutics news (Ticker: VKTX), a resource for investors and traders seeking the latest updates and insights on Viking Therapeutics stock.
Viking Therapeutics, Inc. (NASDAQ: VKTX) is a clinical-stage biopharmaceutical company based in San Diego, specializing in the development of novel therapies for metabolic and endocrine disorders. Focused on creating first-in-class or best-in-class treatments, Viking's research leverages its deep expertise in metabolism to develop innovative therapeutics designed to improve patients' lives.
Viking's pipeline includes three main compounds currently in clinical trials. VK2809, a selective thyroid hormone receptor beta agonist, is being evaluated for the treatment of non-alcoholic steatohepatitis (NASH) and fibrosis. Recent data from a Phase 2b VOYAGE study showed that VK2809 achieved both its primary and secondary endpoints, demonstrating significant reductions in liver fat content and improvements in fibrosis and NASH resolution over a 52-week treatment period.
The company is also advancing VK2735, a dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors, which is being developed for the treatment of metabolic disorders such as obesity. Phase 1 and 2 trials have indicated promising efficacy and safety profiles, with significant reductions in body weight observed in treated patients. Viking is evaluating both subcutaneous and oral formulations of VK2735, aiming to enhance patient convenience and expand market opportunities.
In the realm of rare diseases, Viking is developing VK0214, a selective thyroid hormone receptor beta agonist for the treatment of X-linked adrenoleukodystrophy (X-ALD). Currently in a Phase 1b clinical trial, VK0214 has shown potential benefits in treating the adrenomyeloneuropathy (AMN) form of X-ALD.
Financially, Viking reported a strong cash position of $963 million as of March 31, 2024, following a public offering of common stock. The company's strategic focus on advancing its clinical programs, coupled with its robust financial health, positions it well for future growth and development.
For more information, please visit Viking Therapeutics' website.
Viking Therapeutics, Inc. (VKTX) announced a clinical hold by the FDA on its Phase 1b trial of VK0214 for X-linked adrenoleukodystrophy (X-ALD). The FDA requires an additional preclinical study, specifically a rodent genotoxicity study, before the trial can continue. This hold is not based on any findings from prior studies. The company expects to submit the requested data in Q2 2022, aiming to resume dosing later this year. VK0214 has previously shown promising safety and efficacy results, including reductions in LDL cholesterol and triglycerides.
Viking Therapeutics (NASDAQ: VKTX) announced the initiation of a Phase 1 clinical trial for VK2735, a novel dual agonist targeting GLP-1 and GIP receptors, aimed at treating metabolic disorders. This double-blind, placebo-controlled study will assess safety, tolerability, and pharmacokinetics in healthy adults, with exploratory assessments of body weight and liver fat changes. VK2735 is expected to enhance therapeutic effects compared to existing treatments like semaglutide. The trial marks a significant milestone for Viking, which aims to report topline results later in the year.
Viking Therapeutics (NASDAQ: VKTX) announced that CEO Brian Lian, Ph.D., will present at the H.C. Wainwright BioConnect 2022 Conference from January 10-13, 2022. The presentation will be available online once the conference begins, with a webcast accessible via Viking's website. Viking Therapeutics focuses on developing innovative therapies for metabolic and endocrine disorders, including its lead candidates VK2809 and VK0214, which are in advanced stages of clinical trials.
Viking Therapeutics (NASDAQ: VKTX) will present at the Stifel 2021 Virtual Healthcare Conference from November 15-17, 2021. CEO Brian Lian, Ph.D., is scheduled to speak on November 16 from 4:00 to 4:30 p.m. Eastern. Interested parties can access the presentation via the company's website, with a replay available post-conference. Viking focuses on therapies for metabolic and endocrine disorders, including VK2809, currently in a Phase 2b study for non-alcoholic steatohepatitis.
Viking Therapeutics (VKTX) reported its Q3 2021 financial results with a net loss of $13.2 million ($0.17 per share), compared to a loss of $9.3 million ($0.13 per share) in Q3 2020. The increase in loss was attributed to rising research and development expenses, now totaling $10.8 million, primarily for clinical studies. Viking is advancing its clinical pipeline, including ongoing Phase 2b VOYAGE trial for VK2809 in NASH and Phase 1b trial for VK0214 in X-ALD. The company ended Q3 with $216 million in cash, positioning it well for future developments.
Viking Therapeutics (NASDAQ: VKTX) presented preclinical data on dual GLP-1/GIP agonists at ObesityWeek 2021. The findings demonstrate significant weight loss and metabolic improvements in diet-induced obese mice, with weight reductions of up to 28%, and enhanced glucose and insulin responses compared to vehicle and semaglutide. The study results support the efficacy of dual agonists and provide a foundation for a forthcoming Phase 1 trial of a lead candidate. CEO Brian Lian emphasized the potential of these compounds in advancing treatment for metabolic disorders.
Viking Therapeutics (VKTX), a clinical-stage biopharmaceutical firm, will announce its third-quarter 2021 financial results on November 3, 2021, after market close. A conference call to discuss these results will follow at 4:30 p.m. ET. The company is developing oral therapies for metabolic and endocrine disorders, including VK2809, currently in Phase 2b trials for non-alcoholic steatohepatitis (NASH). VK2809 has shown efficacy in reducing LDL-C and liver fat in prior studies. The firm holds exclusive rights to five therapeutic programs from Ligand Pharmaceuticals.
Viking Therapeutics (NASDAQ: VKTX) announced the presentation of promising preclinical data on novel dual agonists targeting GLP-1 and GIP receptors at ObesityWeek 2021, occurring from November 1-5, 2021. Results from studies in diet-induced obese mice highlight significant weight loss and improved metabolic profiles. The poster presentations will be led by Kader Yagiz, Ph.D. This research could enhance Viking's pipeline of therapies for metabolic and endocrine disorders, further supporting its clinical programs, including VK2809 for NASH and fibrosis.
Viking Therapeutics (NASDAQ: VKTX) will have CEO Brian Lian, Ph.D., present at the H.C. Wainwright 5th Annual NASH Investor Conference on October 12, 2021. The virtual presentation is scheduled for 11:00 – 11:20 a.m. Eastern. Viking is focused on developing innovative therapies for metabolic and endocrine disorders, including VK2809, a selective thyroid hormone receptor beta agonist currently in Phase 2b for NASH. The company is also developing VK0214 for X-linked adrenoleukodystrophy (X-ALD).
Viking Therapeutics, Inc. (NASDAQ: VKTX) announced its participation in four upcoming investor conferences. The events include Citi's 16th Annual Biopharma Virtual Conference (Sept 8-10), H.C. Wainwright's 23rd Annual Global Investment Conference (Sept 13-15), Oppenheimer Fall Healthcare Life Sciences & MedTech Summit (Sept 20-23), and Cantor Fitzgerald Virtual Global Healthcare Conference (Sept 27-30). Presentations will be available online, and webcasts will follow. Viking focuses on innovative therapies for metabolic disorders, with key programs including VK2809 and VK0214 currently in clinical trials.
FAQ
What is the current stock price of Viking Therapeutics (VKTX)?
What is the market cap of Viking Therapeutics (VKTX)?
What is the focus of Viking Therapeutics, Inc.?
What are the main compounds in Viking's clinical pipeline?
What recent achievements has Viking Therapeutics reported?
What financial condition is Viking Therapeutics currently in?
What are the potential treatments being developed by Viking for metabolic disorders?
How does VK2735 work?
What is VK0214 targeting?
What significant clinical milestones has VK2809 achieved?
How is Viking Therapeutics funded for its operations?
Where can I get more information about Viking Therapeutics?
